Trials / Terminated
TerminatedNCT05838742
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain
A Multicentre Randomized, Double-blind, Placebo Controlled, Dose-finding, Phase 2 Study (MARS-17) of GSK3858279 in Adult Participants With Moderate to Severe Pain Due to Knee Osteoarthritis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 314 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3858279 | GSK3858279 will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2023-09-13
- Primary completion
- 2024-08-12
- Completion
- 2024-12-03
- First posted
- 2023-05-03
- Last updated
- 2025-11-10
- Results posted
- 2025-11-10
Locations
93 sites across 13 countries: United States, Argentina, Australia, Canada, China, France, Germany, Japan, Mexico, South Africa, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05838742. Inclusion in this directory is not an endorsement.